The company blamed its Q2 content slate and price increases for the subscriber miss.Technologyread more
Corporate earnings forecasts for the second quarter were lowered so much that companies are easily beating them.Market Insiderread more
The central bank is not normally in the business of easing into an economy that is showing few signs of a recession, generally holding fire until more pronounced signs of a...The Fedread more
IBM's year-over-year revenue has now declined for four quarters in a row. Impact from Red Hat is not yet factored into the company's guidance.Technologyread more
Challenging conditions in the U.S. housing market, along with tighter currency controls by the Chinese government, cause a stunning drop in foreign demand for American homes.Real Estateread more
Prosecutors in Masschusetts have dropped a criminal case against actor Kevin Spacey, who had been accused of groping an 18-year-old man.Politicsread more
House Speaker Nancy Pelosi says she wants her chamber to vote on a debt ceiling and budget deal by July 26.Politicsread more
Philips has acquired a start-up that texts you about your poop. That's Medumo, a Boston-based company, which works with hospitals to guide their patients through common...Technologyread more
The "'Cadillac tax," set to go into effect in 2022, is unpopular with both Republicans and Democrats, who say it punishes the middle class.Health and Scienceread more
His case for gold comes as central banks get more aggressive with policies that devalue currencies and are about to cause a "paradigm shift" in investing.Marketsread more
The declaration comes days after a case of the virus was confirmed in the Congolese city Goma, which borders neighboring country Rwanda.Health and Scienceread more
Johnson & Johnson contributed the most to gains for the Dow Jones industrial average on Monday after analysts at JPMorgan upgraded the stock on expectations of stronger growth in its pharmaceuticals division.
JPMorgan upgraded Johnson & Johnson's stock to overweight from neutral and hiked its price target to $140 from $133, representing a 13.2 percent potential upside from Friday's close of $123.64.
Analyst Michael Weinstein said he expects organic sales growth in the firm's pharma division to "re-accelerate" from 2 percent in the first half of this year to a range of 5-6 percent in the second half. He added that JPMorgan sees organic growth to range between 6 and 7 percent in 2018.
"This should put J&J's pharma growth in 2018 at 2x its pharma peers (3.2%) and enable J&J's overall top-line to accelerate from 1.5-2.0% organic in 1H17 [first-half 2017] to 4.0-4.5% in 2H17 and 4.5-5.0% in 2018," Weinstein said in a note Monday.
"We recognize that this is a notably contrarian call today. J&J is coming off a disappointing first quarter, and the second quarter is going to be just as challenging, owing to $340M in 2Q16 gross-to-net adjustments that make for a particularly tough comp," Weinstein added.
Johnson & Johnson reported mixed first-quarter results on April 19, as earnings per share topped analyst expectations while revenue missed.
"But, ... once J&J gets the second quarter behind it, comps ease considerably, new products should get approved, and clinical trial read-outs become potential catalysts for an improving Pharma business and a reacceleration in top-line growth."